NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Promising Pipeline | NewAmsterdam Pharma's lead candidate obicetrapib shows potential to become a standard-of-care second-line therapy for cardiovascular disease management |
Clinical Milestones | Explore the accelerated timeline for TANDEM study results and the ongoing PREVAIL outcomes study, both crucial for obicetrapib's market prospects |
Market Potential | Analysts project U.S. sales exceeding $1.3 billion, with price targets ranging from $36.79 to $52.05, indicating significant upside potential |
Competitive Edge | Delve into obicetrapib's unique profile as a CETP inhibitor, potentially offering advantages over existing treatments in efficacy, safety, and convenience |
Metrics to compare | NAMS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAMSPeersSector | |
---|---|---|---|---|
P/E Ratio | −17.0x | −1.4x | −0.5x | |
PEG Ratio | −0.41 | 0.00 | 0.00 | |
Price/Book | 3.6x | 2.8x | 2.6x | |
Price / LTM Sales | 44.1x | 8.0x | 3.3x | |
Upside (Analyst Target) | 64.4% | 263.7% | 40.3% | |
Fair Value Upside | Unlock | 29.6% | 5.1% | Unlock |